The FDA cleared two new therapies for vasomotor symptoms of menopause: elinzanetant, a novel nonhormonal agent, and Bayer’s Lynkuet, described by the company as the first dual neurokinin‑targeted therapy to win approval. Regulators based the elinzanetant decision on multinational Phase II/III data showing reductions in hot flashes and night sweats; Bayer emphasized Lynkuet’s differentiated mechanism in its women’s‑health portfolio. Both approvals expand non‑estrogen treatment options for clinicians and patients seeking alternatives to hormone therapy.